البلد: إسرائيل
اللغة: الإنجليزية
المصدر: Ministry of Health
DOXYLAMINE SUCCINATE; PYRIDOXINE (VIT B6) HYDROCHLORIDE
TZAMAL BIO-PHARMA LTD
R06AA09
TABLETS EXTENDED RELEASE
DOXYLAMINE SUCCINATE 20 MG; PYRIDOXINE (VIT B6) HYDROCHLORIDE 20 MG
PER OS
Required
DUCHESNAY INC., CANADA
DOXYLAMINE
BONJESTA is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.Limitations of UseBONJESTA has not been studied in women with hyperemesis gravidarum.
2021-06-17
_ _ BON_PI_TZ_06.2021-00 _ _ _Page 1 of 12 _ SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF MEDICINAL PRODUCT BONJESTA 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Pyridoxine hydrochloride 20 mg Doxylamine succinate 20 mg For the full list of excipients, see section 12. 3. PHARMACEUTICAL FORM Extended release tablets. BONJESTA extended-release tablets are pink, round, film-coated tablets containing 20 mg doxylamine succinate and 20 mg pyridoxine hydrochloride, imprinted on one side with the pink image of a pregnant woman and a “D” on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS BONJESTA is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. LIMITATIONS OF USE BONJESTA has not been studied in women with hyperemesis gravidarum. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Initially, take one BONJESTA extended-release tablet orally at bedtime (Day 1). If this dose adequately controls symptoms the next day, continue taking one tablet daily at bedtime only. However, if symptoms persist on Day 2, increase the daily dose to one tablet in the morning and one tablet at bedtime. The maximum recommended dose is two tablets per day, one in the morning and one at bedtime. Take on an empty stomach with a glass of water _[see Clinical Pharmacology (12.3)]._ Swallow tablets whole. Do not crush, chew, or split BONJESTA tablets. _ _ BON_PI_TZ_06.2021-00 _ _ _Page 2 of 12 _ Take daily and not on an as needed basis. Reassess the woman for continued need for BONJESTA as her pregnancy progresses. 4.3 CONTRAINDICATIONS BONJESTA is contraindicated in women with any of the following conditions: • Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation • Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects of BONJESTA _[see Drug Interactions (7.1)]_ . 5. SPECIAL WARNINGS AND PRECAUTIONS FOR US اقرأ الوثيقة كاملة